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differentiate significant and trivial chemical
hazards and to assess likely risks to humans.
This latter justification can be illustrated by
the following statement: ifall chemicals that
are mutagenic in vitro were mutagenic and
carcinogenic to humans, and if all rodent
carcinogens posed an equal carcinogenic
hazard to humans, then there would be no
role for mechanistic studies. The fact that
these statements are self-evidently untrue
therefore provides the main justification for
the conduct ofmechanistic studies.
The value of the results of mechanistic
studies aimed at differentiating hazards
should be judged solely in terms of the
extent to which they either increase or
decrease the level ofconcern over the poten-
tial hazard posed to humans by exposure to
the substance under study. Within this con-
text, simple experiments, such as confirming
that an in vitromutagen is also mutagenic in
vivo or establishing the effect that changing
the route ofexposure, or the test species, has
on the carcinogenicity ofasubstance, qualify
as mechanistic studies. However, the term is
usually reserved for investigations that pro-
vide a framework within which the rodent
toxicity ofa substance can be explained and
extrapolated to humans.
Loose use ofthe term mechanistic stud-
ies can lead to confusion when the derived
results offer no guidance on human hazard
assessment. For example, it may be interest-
ing to establish that nitrogen mustard is clas-
togenic by virtue ofits ability to bind cova-
lently with DNA, while the similar activity
of etoposide is due to its ability to inhibit
topoisomerase II enzymes, but such knowl-
edge is ofno value for human hazard assess-
ment in the absence ofdata indicating that
one of these mechanisms of clastogenesis is
more relevant to human hazard assessment
than the other. This single example indicates
that when mechanistic data are invoked to
qualify the hazard of a rodent carcinogen,
there is a need to discuss the context ofthose
data and to make clearhow theyshould alter
our perception ofthe human hazard implied
bythe initial test data.
To date, there are no examples of a
mechanism of cancer induction in rodents
that is rigorously established and uniformly
accepted as being of no relevance to
humans. Further, given the potential for
occasional high accidental exposures to
chemicals and the existence ofhuman poly-
morphisms among the enzymes that acti-
vate or detoxify chemicals, and among the
enzymes and processes that maintain genet-
ic integrity, such an example is unlikely
ever to be documented. Nonetheless, there
are several proposed mechanisms of cancer
induction (rodent tumor etiologies) and
tumor types (e.g., B6C3F1 mouse liver
tumors) that carry a high level ofcertainty
regarding their probable irrelevance to
humans. The central issue therefore
becomes whether a given level of certainty
is acceptable or not. Whichever conclusion
is reached in such cases, a compromise will
have been made in the process. So, for
example, if a chemical induces specifically
renal or thyroid gland tumors in a lifetime
rat carcinogenicity bioassay and if those
tumors are preceded by the induction of
ax2u-globulin-mediated nephropathy or
thyroid-stimulating hormone-mediated
thyroid follicular cell proliferation, respec-
tively, then a decision will have to be made
regarding the relevance ofthose tumor eti-
ologies to humans.
The differences evident in the view-
points ofHuff(1) and Dietrich (3) are due
to both different starting premises regard-
ing the value of attempting to separate
mechanisms ofchemical carcinogenesis and
differences in their use and interpretation
of the available mechanistic data for the
cx2u-globulin-mediated nephropathy
mechanism. Those differences are of inter-
est at two levels. First, they lead to identifi-
cation of the key data by which to assess
whether or not humans will be subject to
this particular rodent tumor etiology.
Uncertainties over the sufficiency and the
significance of those data remain a valid
subject for future research. Second, the dif-
ferent viewpoints expressed confirm that
we have some way to go before we can all
share a common motivation for undertak-
ing mechanistic studies. Put simply, we will
make no useful progress until we can share
the motivation of attempting to improve
human hazard assessments within the limit-
ed confines of the resources available for
the task, mindful that compromises will
have to be made ifwe are to distinguish, for
example, the human hazards posed by
exposure to the rodent kidney carcinogens
limonene and diethyl nitrosamine. That
motivation will lead only to rational and
balanced discussion of the relevant peer-
reviewed data. As summarized in the old
Chinese adage, "if you want to find the
truth about an issue, don't take either side."
Attempts to guard the scientific high
ground and to search for certainty, ostensi-
bly on behalf of less well-informed col-
leagues, or attempts to dismiss rodent car-
cinogenicity data by reference to insecure
and preliminary mechanistic constructs
must be equally resisted.
The success or failure ofthe margin of
exposure (MOE) approach to nongenotox-
ic carcinogen hazard assessment proposed
by the U.S. EPAwill depend largely on the
extent to which such common ground can
be found and secured in the future.
JohnAshby
Zeneca Central Toxicology Laboratory
Alderley Park, Cheshire, United Kingdom
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o2u-Globulin Nephropathy
and Ravens: Do Ravens of a
Different Feather Flock
Together?
The scientific community is well served by
the continued interest in mechanisms of
x2u-globulin nephropathy and its poten-
tial relationship to nephrocarcinogenesis in
rodents. The article by Huff (1), com-
mented on byAshby (2), and with a subse-
quent reply by Huff(3) sparked a renewed
polemic. In addition, a letter by Dietrich
(4) further fuels this scholarly debate.
Having contemplated the diverse opin-
ions from these authors, we are concerned
that some of the statements based on pub-
lished data from our laboratories (5-7)
might be viewed in different context than
originally presented, leading to potential
misinterpretations. To clarify these state-
ments from other scientists, we feel that it is
necessary to touch upon the following facts.
Over the last decade, we have developed
extensive preclinical safety evaluation data
to support the human use of gabapentin.
Gabapentin is a safe and effective drug for
epilepsy based on rigorous review by regula-
tory agencies worldwide. From these stud-
ies, risk benefit comparisons were made
between animal and human dosages. Wistar
rats in the 2-year carcinogenicity bioassay
showed significantly higher gabapentin
exposures (as measured by plasma concen-
trations and area under the curve) than
humans at therapeutic exposures.
When exposed to gabapentin for 2
years at 10-15 multiples of the human
exposure, rats developed mild a2u protein
accumulation as judged by histomorpho-
logic examination. After 13 weeks ofexpo-
sure, the incidence of ux2u-globulin accu-
mulation was similar across the treatment
and control groups, and the degree of
severity was higher in the treated groups.
The extent ofa2u protein accumulation in
the kidneys of male rats treated with
gabapentin diminished after 52 weeks,
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whereas the severity ofspontaneous chronic
nephropathy in treated male rats relative to
controls increased from 52 and 104 weeks.
As a result of the current discussion in
the literature (3), the kidney specimens were
reanalyzed for the hallmarks of x2u-globulin
nephropathy sequelae, namely the presence
of granular casts and linear mineralization
(8). These changes were not observed in
male rats receiving 250, 1,000, or 2,000
mg/kg ofgabapentin for 2 years. In terms of
proliferative effects, therewere 3 foci ofatyp-
ical hyperplasia of renal tubules: 2/50 were
found in male rats at 1,000 mg/kg and 1/50
male rats at 2,000 mg/kg of gabapentin.
These kidney examinations in the 2-year
study included four sections (two from each
kidney) from every animal in the group
(50/sex/group), amounting to 1,600 kidney
sections in the 2-year rat study. This stan-
dard procedure seems to adequately sample
the kidney.
Reference was made to renal accumula-
tion ofgabapentin and to its ability to bind
a2u-globulin. Metabolic disposition data
revealed no differences in the accumulation
of gabapentin in the kidney of male and
female rats. Gabapentin distributes rapidly
to the kidney in both sexes, and approxi-
mately 10-12% ofthe dose is found at 2-
hr post-dose. The elimination decay is
rapid, and 0.20-0.14 gabapentin radioe-
quivalents in micrograms per gram are
found at 12 hr post-dose. Full profile toxi-
cokinetic studies have shown linear kinet-
ics without accumulation, and elimination
follows rapid clearance from the plasma
and organ compartments. Recoveries in
the mass balance studies yielded 99% or
more ofthe administered dose.
Why such a diverse series of chemicals
causes a putatively similar microglobulin
nephropathy with (i.e., unleaded gasoline)
and without (i.e., gabapentin) nephrocar-
cinogenesis is intriguing.
Evaluation ofthe gabapentin data does
not prove or disprove that a2u-globulin
accumulation precedes, promotes, or caus-
es renal cancer in rats over a 2-year con-
stant exposure at toxicity-limiting doses.
We propose that although morphofunc-
tional features may appear similar for all
documented cases of this xenobiotic-
induced nephropathy, different mecha-
nisms may be operative. Alternatively, a
structural comparison of the x2u
microglobulin species would assert this
microglobulin not to be the same in all
cases when induced by the diverse chemi-
cals. The work by Hildebrand et al. (9)
would indicate some support to this
notion. In the case ofgabapentin, in which
we have substantial data on hand, it is dif-
ficult to advocate existing mechanisms
because ofthe drug's lack ofmetabolism or
biotransformation, lack of serum protein
binding, or lack of significant organ accu-
mulation. It remains unanswered whether
data on cell proliferation or specific 4x2u-
globulin binding to renal tubule proteins
would substantiate current mechanisms.
Clearly new data, rather than new assump-
tions, will give fresh insight to our under-
standing ofthe a2u nephropathy puzzle.
FelixA. de la Iglesia
Alexander W. Gough
Robert E. Sigler
Pathology and Experimental Toxicology
Parke-Davis Pharmaceutical Research
Division, Warner-Lambert Company
Ann Arbor, Michigan
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Weight of Evidence Versus
Weight of Speculation to
Evaluate the o2u-Globulin
Hypothesis
In response to a challenge fromJohn Ashby
(1) to identify chemicals that demonstrate
inconsistency with the a2u-globulin
nephropathy/rat kidney cancer hypothesis,
James Huff (2) described the responses of
seven relevant chemicals in an accompany-
ing correspondence. Evidently that response
hit a sensitive nerve in Daniel Dietrich (3),
resulting in his needless attackon those who
profess different views on this issue.
Dietrich claims that the a2u-globulin
mechanism has been "established and
meticulously proven" and chastises those
who "choose to ignore the obvious" by
questioning the validity of this "accepted
mechanism." To Dietrich, those who
doubt this hypothesis are guilty of "misin-
terpretation of available data." Would
Dietrich similarly criticize Short et al. (4),
including his own mentorJames Swenberg,
for acknowledging that "the exact mecha-
nism of cellular damage in cc2u [globulin]
nephropathy is unknown" or the EPA Risk
Assessment Forum (5) for concluding that
the at2u-globulin syndrome "should be
considered a satisfactory working hypothe-
sis but not a proven mechanism of action
to describe renal tubule cancer in male rats
exposed to CIGA" [chemicals that induce
tx2u-globulin accumulation]?
Rather amusing in this debate is that
Dietrich does exactly what he wrongfully
accuses Huff of doing, namely, misinter-
preting data and misrepresenting various
study findings to support his own view-
point. We chose to use only three of the
many distortions in Dietrich's letter for
illustration. First, Dietrich claims that
Partanen et al. (6) attributed the elevated
risk ofrenal cell cancer in humans exposed
to gasoline "to the tetraethyl-lead content
of the gasoline and not to the gasoline
(volatile hydrocarbons) itself." That is
wrong. Partanen et al. (6) actually wrote
that "our results suggest that some hydro-
carbon constituents) or additives) ofgaso-
line are conducive to renal cell cancer in
humans," and although "tetraethyl lead is
capable ofdermal entrance . .. the amount
of lead intake is probably low in the jobs
with typical dermal exposure to gasoline."
Furthermore, a recent epidemiological
study ofworkers exposed to gasoline vapors
(service station workers in the Nordic
countries) found a 30% excess risk of kid-
ney cancer with no excess risk ofleukemia
(7). The kidney cancer findings in humans
exposed to gasoline vapors correspond to
previously reported kidney cancer findings
in male rats, which Dietrich ironically dis-
misses as irrelevant to human risk because
ofa2u-globulin accumulation.
Second, Dietrich attempts to explain the
nonconcordance between lindane-induced
a2u-globulin nephropathy and the lack ofa
male rat kidney tumor response byspeculat-
ing about relationships among exposure to
lindane, testicular atrophy, serum testos-
terone levels, and a2u-nephropathy.
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